Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Anthony V. D'Amico, MD, PhD

Radiation Oncology

Make an Appointment

Anthony V. D americas top doctors


  • Chief, Division of Genitourinary Radiation Oncology
  • Institute Physician
  • Professor of Radiation Oncology, Harvard Medical School

Clinical Interests

  • Bladder cancer
  • Prostate cancer
  • Renal cancer
  • Testicular cancer

Diseases Treated

Contact Information

  • Appointments857-215-1489
  • Office Phone Number857-215-1489
  • Fax617-394-2668


Dr. D'Amico is a professor of Radiation Oncology at Harvard Medical School and is the chief of Genitourinary Radiation Oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute. He received his PhD in Radiation Physics from the Massachusetts Institute of Technology in 1986, and then his MD from the University of Pennsylvania in 1990, where he also served as a resident and then chief resident in 1994. He has gained international recognition for his work in detection, staging, and treatment of prostate cancer with over 140 peer-reviewed publications, and has co-edited four textbooks in Urologic Oncology. His prostate cancer research is funded by federal grants from the NIH, NCI, DOD and MA DPH.

Board Certification:

  • Radiation Oncology, 1995


  • Hospital of the University of Pennsylvania
  • University of Pennsylvania School of Medicine, Radiation Oncology

Medical School:

  • University of Pennsylvania School of Medicine


D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason Score < 7. Cancer 2000; 88:2110-2115.

D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Art M, Tomaszewski JE, Wein A. The combination of the preoperative PSA level, biopsy Gleason score, percent positive biopsies and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55:752-576.

D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J. Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland. Urology 2000; 55:783-787.

D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff P, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant therapy trials. J Clin Oncol 2000; 18:3240-3246.

D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Schultz D, Cote K. Tomaszewski JE, Wein A. Endorectal magnetic resonance imaging as a predictor of biochemical outcome following radical prostatectomy for men with clinically localized prostate cancer. J Urol 2000; 164:759-763.

D'Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 2000; 163:1797-1801.

D'Amico AV, Cormack R, Kumar S, Tempany CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clincially localized prostate cancer. J Endourology 2000; 14:367-370.

D'Amico AV, Tempany CM, Cormack R, Hata N, Jinzaki M, Tuncali K, Weinstein M, Richie JP. Transperineal magnetic resonance image guided prostate biopsy. J Urol 2000; 164:385-387.


Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions